Related Experiment Video
Updated: Jan 8, 2026

In vitro Assessment of Cardiac Reprogramming by Measuring Cardiac Specific Calcium Flux with a GCaMP3 Reporter
Published on: February 22, 2022
miR-30a-5p preserves cardiac homeostasis by reprogramming metabolic checkpoints in hypertrophic cardiomyopathy
Xiao-Cheng Zhang1, Chan Wu1, Yun-Da Li1
1Xiamen Cardiovascular Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian, 361009, China.
Insights
MicroRNA-30a-5p protects against pathological cardiac hypertrophy by maintaining mitochondrial function and redox balance. This study reveals its therapeutic potential in treating heart conditions.
Area of Science:
- Cardiovascular Biology
- Molecular Cardiology
- MicroRNA Therapeutics
Background:
- MicroRNA-30a-5p (miR-30a-5p) is implicated in myocardial infarction but its role in cardiac hypertrophy is unclear.
- Pathological cardiac hypertrophy is a major risk factor for heart failure.
Purpose of the Study:
- To investigate the therapeutic potential and molecular mechanisms of miR-30a-5p in cardiac hypertrophy.
- To elucidate the role of miR-30a-5p in cardiac function, remodeling, and mitochondrial homeostasis.
Main Methods:
- Transgenic knockout mice and angiotensin II (Ang II)-induced models of cardiac hypertrophy.
- Transverse aortic constriction (TAC) to induce pressure overload.
- Cellular assays, RNA-sequencing, and mitochondrial function analysis.
Main Results:
- miR-30a-5p was upregulated in cardiac hypertrophy models.
- miR-30a-5p deficiency worsened hypertrophy and cardiac remodeling.
- miR-30a-5p overexpression protected against hypertrophy-induced dysfunction and fibrosis.
- miR-30a-5p preserved mitochondrial bioenergetics and reduced oxidative stress.
Conclusions:
- miR-30a-5p acts as a protective factor against pathological cardiac hypertrophy.
- Therapeutic strategies targeting miR-30a-5p may preserve mitochondrial integrity and redox homeostasis in hypertrophic hearts.
Abstract:
Emerging evidence has established the regulatory role of miR-30a-5p in myocardial infarction through multifaceted mechanisms. However, its functional significance in pathological cardiac hypertrophy remains incompletely elucidated. This study systematically investigates the therapeutic potential and molecular underpinnings of miR-30a-5p in cardiac hypertrophy using complementary experimental approaches. We employed transgenic knockout murine models combined transverse aortic constriction (TAC)- and an angiotensin II (Ang II)-induced cardiac hypertrophy paradigms to evaluate the functional consequences of miR-30a-5p modulation on cardiac function, cardiac remodeling, and mitochondrial homeostasis. Multidisciplinary strategies incorporating cellular assays, RNA-sequencing profiling, and mitochondrial functional analysis were implemented to decipher mechanistic pathways. Notably, myocardial miR-30a-5p expression was significantly upregulated in both murine and cellular hypertrophy models. Genetic ablation of miR-30a-5p spontaneously developed a hypertrophic phenotype, while miR-30a-5p deficiency exacerbated TAC- or Ang II-induced pathological cardiac remodeling. Conversely, miR-30a-5p overexpression conferred significant protection against hypertrophy-associated ventricular dysfunction and interstitial fibrosis. Transcriptomic profiling revealed distinctive enrichment of mitochondrial bioenergetics and metabolic reprogramming pathways in knockout mice following TAC challenge, positioning mitochondrial integrity as a critical mediator of miR-30a-5p-dependent cardioprotection. Mechanistic studies further demonstrated that miR-30a-5p preserves myocardial mitochondrial function, enhances respiratory chain efficiency, and attenuates reactive oxygen species generation during hypertrophic stress. Collectively, our findings demonstrate that miR-30a-5p confers protection against pathological cardiac hypertrophy, mediated through the preservation of mitochondrial bioenergetic regulation and redox homeostasis.
Related Concept Videos
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cardiomyopathy II: Dilated Cardiomyopathy

